Semax intranasal dosing: the 0.1% vs 1% concentration guide, published clinical protocols, olfactory delivery mechanism, and why the route of administration matters for BDNF effects.
Semax is a synthetic heptapeptide derived from the ACTH(4-7) sequence (Met-Glu-His-Phe-Pro-Gly-Pro), originally developed and registered in Russia for acute stroke, head trauma, and cognitive enhancement applications. It is administered intranasally — a route that exploits the olfactory neuroepithelium's direct axonal pathway to the olfactory bulb and limbic system, bypassing the blood-brain barrier to achieve meaningful CNS concentrations without systemic injection. Understanding the intranasal dosing arithmetic, the distinction between the 0.1% and 1% formulations used in research and clinical practice, and the evidence base for each dose range is essential context for anyone evaluating the semax research literature.
- The registered Russian clinical formulation is 0.1% semax (1 mg/mL). The higher-concentration 1% formulation (10 mg/mL) is also commercially available and used for lower-drop protocols achieving the same total dose.
- Russian clinical registry doses for neurological indications: 200–600 µg per day in 2–3 divided doses. Intranasal spray volumes are typically 50–100 µL per nostril per administration.
- Semax upregulates BDNF, NGF, and dopaminergic receptor expression in the hippocampus and prefrontal cortex — mechanisms that support its cognitive-enhancing profile.
- Intranasal delivery routes semax via the olfactory-trigeminal pathway to the CNS, where systemic plasma concentrations are less relevant than CNS tissue concentrations — which are not measurable non-invasively in humans.
- N-acetyl semax amidate (NASA) uses terminal modifications (N-acetylation + C-terminal amidation) to increase metabolic stability compared to standard semax.
Concentration arithmetic: 0.1% vs 1% semax
The two commercially available semax concentrations differ by a factor of 10 in dose per drop volume:
| Formulation | Concentration | Dose per 50 µL (1 nostril drop) | Dose per 100 µL |
|---|---|---|---|
| Semax 0.1% | 1 mg/mL (1000 µg/mL) | 50 µg | 100 µg |
| Semax 1% | 10 mg/mL (10,000 µg/mL) | 500 µg | 1,000 µg |
The registered Russian 0.1% formulation allows fine-grained dose titration — the typical clinical dose of 200–600 µg/day is achieved with 2–6 × 50 µL doses distributed across nostrils and timing. The 1% formulation, being 10x more concentrated, requires careful volume control to avoid wide dose variability. A small nasal spray pump typically delivers approximately 100 µL per actuation; with 1% semax this would be 1,000 µg (1 mg) per spray — substantially above the lower clinical dose range in a single actuation.
Intranasal delivery: the olfactory pathway to the CNS
Semax's intranasal route is not merely a convenient alternative to injection — it is a pharmacologically distinct delivery pathway. The nasal mucosa contains two distinct populations relevant to CNS delivery:
- Olfactory neuroepithelium (in the superior nasal turbinate): The olfactory sensory neurons project unmyelinated axons (olfactory fila) through the cribriform plate directly to the olfactory bulb — a direct anatomical connection between the nasal cavity and the brain that bypasses the blood-brain barrier entirely. Compounds absorbed through the olfactory epithelium can reach the olfactory bulb and thence the limbic system, prefrontal cortex, and hippocampus without systemic circulation.
- Respiratory epithelium and nasal vasculature: Conventional nasal absorption into the bloodstream, providing systemic exposure that then requires BBB crossing for CNS access.
For semax, the olfactory pathway is the pharmacologically relevant route. Peptides delivered via the olfactory neuroepithelial pathway can achieve CNS concentrations substantially above what would be predicted from systemic plasma levels alone. Banks et al. (2004) [PMID 15026187] characterized the blood-brain barrier properties of intranasal peptide delivery, establishing that the olfactory pathway provides access to specific brain regions (olfactory bulb, limbic system, brainstem) at efficiency substantially higher than systemic injection for polar peptides that cross the BBB poorly.
The practical implication: semax's intranasal dose is not directly comparable to an equivalent IV dose in terms of CNS exposure. CNS concentration after intranasal semax is route-dependent and cannot be estimated from peripheral plasma concentration measurement alone.
Published clinical doses from Russian registry
Semax is registered in Russia under the Ministry of Health registration number P N013948/01. The registered indications include: acute ischemic stroke, transient ischemic attack, optic nerve atrophy, and cognitive dysfunction. The registered clinical protocols specify:
- Acute ischemic stroke/TIA: 12–18 µg/kg/day intranasally, divided into 3 daily administrations, for 10–14 days. For a 70 kg patient: approximately 840–1260 µg/day total, or 280–420 µg per administration.
- Optic nerve atrophy: 200–300 µg/day for 14 days
- Cognitive dysfunction (outpatient): 200–600 µg/day for 14–28 days
Kolomin et al. (2013) [PMID 24004811] investigated semax's gene expression effects in the hippocampus using rodent models at doses scaled to the human clinical range, finding upregulation of BDNF, TrkB (the BDNF receptor), NGF, and dopamine receptor D1 and D4 gene expression. The BDNF upregulation in hippocampal tissue is one of the primary mechanistic bases proposed for semax's cognitive effects — BDNF is the key neurotrophin for hippocampal synaptic plasticity, LTP (long-term potentiation), and spatial memory formation.
Timing and administration protocol
The head position during intranasal delivery significantly affects whether the dose reaches the olfactory neuroepithelium (superior turbinate) vs the respiratory epithelium (inferior turbinate, which drains posteriorly into the nasopharynx and contributes to systemic absorption rather than olfactory CNS access).
Optimal technique for olfactory delivery:
- Tilt head back approximately 30–45 degrees or use the lateral supine position (ear to shoulder)
- Apply drops to the superior nasal cavity by aiming the drop application toward the superior turbinate (back and upward from the nostril opening)
- Remain in position for 1–2 minutes to allow absorption before returning to upright
- Sniff gently after administration to spread the liquid across the superior turbinate — avoid forceful sniffing that would draw the solution into the nasopharynx and contribute only to systemic absorption
Russian clinical trial protocols for semax specifically instruct the "Mygind position" (supine with head slightly hyperextended and tilted 45°) for optimal olfactory delivery. This administration technique is rarely specified in community-level research protocols, potentially contributing to dose variability in non-clinical use.
BDNF and dopaminergic effects: the mechanism evidence
Semax's cognitive-enhancing mechanism involves upregulation of BDNF (brain-derived neurotrophic factor), its TrkB receptor, and dopaminergic neurotransmission in prefrontal-hippocampal circuits. Dolotov et al. (2006) [PMID 17038218] demonstrated that intranasal semax at doses in the 50–250 µg/kg range produced BDNF mRNA upregulation in the hippocampus and basal forebrain that persisted for 24 hours following a single administration. The BDNF upregulation was dose-dependent across this range and specifically linked to activation of the TrkB-PLC-γ signaling cascade — the pathway that mediates synaptic strengthening during memory consolidation.
The dopaminergic component — particularly D1 receptor upregulation in the prefrontal cortex — is relevant to working memory and attention. The prefrontal D1 system is exquisitely sensitive to dopamine concentration (inverted-U dose-response for cognitive performance), and semax's modest D1 upregulation may improve prefrontal circuit efficiency without the saturation effects produced by direct dopamine agonists or stimulants.
Standard semax vs N-acetyl semax amidate
N-acetyl semax amidate (NASA) modifies both termini of the standard semax sequence:
| Compound | N-terminus | C-terminus | Stability vs standard |
|---|---|---|---|
| Standard semax | Free amino group | Free carboxyl (–COOH) | Reference |
| N-acetyl semax amidate | Acetyl group | Amide (–CONH2) | Substantially increased vs serum peptidases |
NASA's enhanced stability against aminopeptidase (N-acetylation blocks N-terminal cleavage) and C-terminal peptidases (amidation protects the C-terminal carboxyl) extends the effective half-life in nasal mucosa and plasma, potentially increasing the bioavailable fraction that reaches the olfactory neuroepithelium before enzymatic degradation. Dose conversion between standard semax and NASA cannot be made from molar equivalence alone due to the differing tissue penetration and stability profiles.
Frequently asked questions
What is the typical intranasal dose of semax?
Russian clinical registry protocols for cognitive indications specify 200–600 µg/day in 2–3 divided doses. For the 0.1% formulation (1 mg/mL), this corresponds to 200–600 µL total daily volume. Most research-use protocols use the lower range (200–300 µg/day) for sustained multi-week courses and higher doses (600–1,260 µg/day) for acute neurological indication contexts.
What is the difference between semax 0.1% and 1%?
Semax 0.1% contains 1 mg/mL (1,000 µg/mL); 1 drop of ~50 µL delivers approximately 50 µg. Semax 1% contains 10 mg/mL (10,000 µg/mL); the same 50 µL drop delivers 500 µg — ten times more. The 0.1% formulation allows fine-grained dose titration; the 1% requires careful volume control and is typically used with smaller drop volumes or to reduce administration frequency while achieving equivalent daily doses.
Does intranasal semax reach the brain?
Yes, via the olfactory neuroepithelium in the superior nasal turbinate. Olfactory sensory neuron axons project directly through the cribriform plate to the olfactory bulb without crossing the blood-brain barrier. This provides direct CNS access to olfactory bulb, limbic system, and prefrontal cortex for compounds applied to the superior nasal epithelium. Optimal delivery technique (head tilt, Mygind position) targets the superior turbinate to maximize olfactory vs respiratory epithelial absorption.
How long does semax take to work?
Rodent studies show BDNF mRNA upregulation in the hippocampus within hours of intranasal semax, with peak effects at 24 hours and maintained upregulation at 48–72 hours following a single administration. Acute cognitive effects (working memory, attention) reported in human subjects begin within 15–60 minutes following intranasal administration. Sustained course effects over 14–28 days show progressive accumulation in BDNF levels and neuroplasticity markers, consistent with the cumulative nature of neurotrophin-dependent synaptic remodeling.
This article is for educational and research reference purposes only. Semax is registered as a pharmaceutical in Russia but is not FDA-approved. Dosing information presented reflects published clinical literature and should not be used as a basis for self-administration.